NCT05406505

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Effect of Adjuvant Dapagliflozin on Improving the Treatment of Congestion in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), increases natriuresis alone and synergistically when combined with loop diuretics in patients with AHF without increasing renin angiotensin- aldosterone activity. Thus, adding SGLT2i to the standard loop diuretic therapy might confer additional decongestive and natriuretic benefits while avoiding the adverse electrolyte abnormalities and neurohormonal activation associated with other diuretic combination. These potential benefits may help with improved clinical outcomes, but clinical evidence is still lacking.

Conditions

• Acute Heart Failure

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg Tab	patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
OTHER	Placebo	patients will receive placebo and standard care.

Timeline

• Start date: 2022-04-25
• Primary completion: 2023-05-01
• Completion: 2023-07-01
• First posted: 2022-06-06
• Last updated: 2023-08-04

Locations

1 site across 1 country: Egypt